-
1 Comment
Cadila Healthcare Limited is currently in a long term uptrend where the price is trading 26.5% above its 200 day moving average.
From a valuation standpoint, the stock is 35.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Cadila Healthcare Limited's total revenue rose by 3.2% to $38B since the same quarter in the previous year.
Its net income has increased by 41.0% to $5B since the same quarter in the previous year.
Finally, its free cash flow grew by 84.7% to $25B since the same quarter in the previous year.
Based on the above factors, Cadila Healthcare Limited gets an overall score of 5/5.
Exchange | NSE |
---|---|
CurrencyCode | INR |
ISIN | INE010B01027 |
Sector | Healthcare |
Industry | Pharmaceuticals |
Beta | 0.64 |
---|---|
PE Ratio | 7.43 |
Target Price | 581.58 |
Dividend Yield | 0.0% |
Market Cap | 354B |
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company provides products in the therapeutic areas of pain management, neurology, liver diseases, and other areas. It also offers consumer wellness products, such as SugarFree and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CADILAHC.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025